COVID-19 or treatment associated immunosuppression may trigger hepatitis B virus reactivation: A case report

BACKGROUND: Since the initial recognition of coronavirus disease 2019 (COVID-19) in Wuhan, this infectious disease has spread to most areas of the world. The pathogenesis of COVID-19 is yet unclear. Hepatitis B virus (HBV) reactivation occurring in COVID-19 patients has not yet been reported. CASE S...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yi-Feng, Yu, Wan-Jun, Jiang, Yu-Hua, Chen, Yin, Zhang, Bo, Zhen, Rui-Bing, Zhang, Jun-Tao, Wang, Yi-Ping, Li, Qiang, Xu, Feng, Shi, Yan-Jun, Li, Xian-Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8283611/
https://www.ncbi.nlm.nih.gov/pubmed/34307577
http://dx.doi.org/10.12998/wjcc.v9.i19.5266
Descripción
Sumario:BACKGROUND: Since the initial recognition of coronavirus disease 2019 (COVID-19) in Wuhan, this infectious disease has spread to most areas of the world. The pathogenesis of COVID-19 is yet unclear. Hepatitis B virus (HBV) reactivation occurring in COVID-19 patients has not yet been reported. CASE SUMMARY: A 45-year-old hepatitis B man with long-term use of adefovir dipivoxil and entecavir for antiviral therapy had HBV reactivation after being treated with methylprednisolone for COVID-19 for 6 d. CONCLUSION: COVID-19 or treatment associated immunosuppression may trigger HBV reactivation.

Ejemplares similares